Rocket Pharmaceuticals
RCKT
126 hedge funds and large institutions have $1.26B invested in Rocket Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 44 reducing their positions, and 12 closing their positions.
800% more call options, than puts
Call options by funds: $882K | Put options by funds: $98K
67% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 12
11% more capital invested
Capital invested by funds: $1.14B → $1.26B (+$123M)
6% more funds holding
Funds holding: 119 → 126 (+7)
1.77% more ownership
Funds ownership: 98.35% → 100.12% (+1.8%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
7% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$23.4M |
| 2 |
Goldman Sachs
New York
|
+$11.4M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$6.28M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.04M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$5.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$6.16M |
| 2 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$6.05M |
| 3 |
Westfield Capital Management
Boston,
Massachusetts
|
-$5.25M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.67M |
| 5 |
Millennium Management
New York
|
-$4.01M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
126
Millennium Management
New York
| $962 | -$4.01M | -162,904 | -79% |
|
|
TCM
127
Tekla Capital Management
Boston,
Massachusetts
| – | -$6.05M | -289,029 | Closed |
|
|
LGM
128
Logos Global Management
San Francisco,
California
| – | -$3.14M | -150,000 | Closed |
|
|
MWNA
129
Marshall Wace North America
New York
| – | -$1.3M | -61,872 | Closed |
|
|
DM
130
Deerfield Management
New York
| – | -$1.11M | -53,043 | Closed |
|
|
FAM
131
Fred Alger Management
New York
| – | -$460K | -22,000 | Closed |
|
|
CSS
132
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$194K | -9,261 | Closed |
|
|
CAN
133
Cetera Advisor Networks
El Segundo,
California
| – | -$112K | -5,356 | Closed |
|
134
Rockefeller Capital Management
New York
| – | -$99K | -4,743 | Closed |
|
|
FC
135
FORA Capital
Miami,
Florida
| – | -$63K | -3,022 | Closed |
|
|
KPW
136
Kore Private Wealth
New York
| – | -$36K | -1,750 | Closed |
|
|
AI
137
ArchPoint Investors
Coral Gables,
Florida
| – | -$31K | -1,500 | Closed |
|
|
PHK
138
Point72 Hong Kong
Hong Kong
| – | -$23K | -1,120 | Closed |
|
RCKT Hedge Fund Activity: Q3 2020 in Review
126 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Rocket Pharmaceuticals (RCKT) for Q3 2020, worth a combined $1.26B — up 11% from $1.14B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new RCKT positions and 12 closed out — a net gain of 8 holders — while 41 added to existing stakes and 44 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $23.4M. The largest seller was Ghost Tree Capital, cutting an estimated $6.16M.
- 126 institutional investors held Rocket Pharmaceuticals (RCKT) as of Q3 2020, up from 119 in Q2 2020.
- Funds reported $1.26B of Rocket Pharmaceuticals stock for Q3 2020, up 11% quarter-over-quarter.
- 20 funds opened new Rocket Pharmaceuticals positions in Q3 2020 and 12 closed out, a net change of +8 holders.
- The largest Rocket Pharmaceuticals buyer in Q3 2020 was T. Rowe Price Associates, an estimated $23.4M added.
- The largest Rocket Pharmaceuticals seller in Q3 2020 was Ghost Tree Capital, an estimated $6.16M sold.
Based on aggregated 13F filings for Q3 2020.